Cancer最新文献

{"title":"Defining concepts in cancer survivorship","authors":"Michelle A. Mollica PhD, MPH, RN, OCN, Michelle Doose PhD, MPH, Crystal Reed MHA, Emily Tonorezos MD, MPH","doi":"10.1002/cncr.70039","DOIUrl":"10.1002/cncr.70039","url":null,"abstract":"<p>The National Cancer Institute’s Office of Cancer Survivorship (OCS) was established in 1996 in response to a call from survivor advocates, in recognition of the growing number of people surviving cancer for long periods of time and their poorly understood needs. The mission of OCS is to support research that examines and addresses the long- and short-term physical, psychological, social, and economic effects of cancer and its treatment among survivors of all ages and stages and their caregivers and families.<span><sup>1</sup></span> This work is accomplished by 1) advancing scientific research; 2) supporting investigators and training to foster a robust network of extramural cancer survivorship research leaders; 3) communicating and collaborating with internal and external survivorship experts; and 4) promoting continued growth and sustained improvement in cancer survivorship care.</p><p>Survivor advocates, who saw the creation of OCS as a culmination of their efforts, also started a movement in calling themselves cancer survivors. Concurrently, researchers began to learn more about concerns and needs related to treatment and survivorship. For cancer survivors, advocates, and researchers, OCS has and continues to serve as the lead in developing a taxonomy of key concepts related to cancer survivorship and caregiving. The purpose of this article is to provide an update on common definitional terms, including cancer survivor, cancer survivorship, cancer survivorship care, and cancer survivorship research. These definitions were developed through a consensus process that included a comprehensive review of the literature and meetings with survivor advocates and subject matter experts.</p><p>An individual is considered a cancer survivor from the time of diagnosis through the balance of life,<span><sup>2, 3</sup></span> and it is recognized that people experience a cancer diagnosis alongside the many events and phases of their lives (Figure 1). There are many types of survivors, including those living with cancer and those free of cancer. This term is meant to encompass the population with a history of cancer rather than to assign an individual label that may or may not resonate with all survivors. Although each individual’s experience as a survivor is unique, there are different types of cancer survivors, including those who are diagnosed with early-stage cancer, those who are diagnosed with advanced or metastatic cancer or who progress to metastatic cancer, and those who are diagnosed with or progress to end-stage cancer.<span><sup>4</sup></span> Goals of care for survivors, including being treated for curative intent or to maximize quality of life, may vary based on several factors, including cancer type, treatment(s) received, age, and prognosis.</p><p>Cancer survivorship is a complex state of being. It includes the perspectives, needs, health, and the physical, psychological, social, and economic challenges experienced by survivors and caregive","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 16","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70039","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144832503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence across the cancer care continuum","authors":"Irbaz Bin Riaz MD, PhD,&nbsp;Muhammad Ali Khan MD,&nbsp;Travis J. Osterman DO, MS","doi":"10.1002/cncr.70050","DOIUrl":"10.1002/cncr.70050","url":null,"abstract":"<p>Artificial intelligence (AI) holds significant potential to enhance various aspects of oncology, spanning the cancer care continuum. This review provides an overview of current and emerging AI applications, from risk assessment and early detection to treatment and supportive care. AI-driven tools are being developed to integrate diverse data sources, including multi-omics and electronic health records, to improve cancer risk stratification and personalize prevention strategies. In screening and diagnosis, AI algorithms show promise in augmenting the accuracy and efficiency of medical image analysis and histopathology interpretation. AI also offers opportunities to refine treatment planning, optimize radiation therapy, and personalize systemic therapy selection. Furthermore, AI is explored for its potential to improve survivorship care by tailoring interventions and to enhance end-of-life care through improved symptom management and prognostic modeling. Beyond care delivery, AI augments clinical workflows, streamlines the dissemination of up-to-date evidence, and captures critical patient-reported outcomes for clinical decision support and outcomes assessment. However, the successful integration of AI into clinical practice requires addressing key challenges, including rigorous validation of algorithms, ensuring data privacy and security, and mitigating potential biases. Effective implementation necessitates interdisciplinary collaboration and comprehensive education for health care professionals. The synergistic interaction between AI and clinical expertise is crucial for realizing the potential of AI to contribute to personalized and effective cancer care. This review highlights the current state of AI in oncology and underscores the importance of responsible development and implementation.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 16","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70050","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144832497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort","authors":"Sun Young Rha MD, PhD,&nbsp;Eduardo Castanon MD,&nbsp;Sanjeev Gill MBBS, FRACP,&nbsp;Helene Senellart MD,&nbsp;Juanita Lopez MD, PhD,&nbsp;Iván Márquez-Rodas MD, PhD,&nbsp;Iván Victoria MD,&nbsp;Tae Min Kim MD, PhD,&nbsp;Zarnie Lwin MBBS, FCP, FRACP,&nbsp;Michael C. Burger MD,&nbsp;Matteo Simonelli MD,&nbsp;Philippe A. Cassier MD, PhD,&nbsp;Andrew E. Hendifar MD,&nbsp;Paolo A. Ascierto MD,&nbsp;Corina Dutcus MD,&nbsp;Chinyere E. Okpara PhD,&nbsp;Razi Ghori PhD,&nbsp;Fan Jin MD,&nbsp;Roman Groisberg MD,&nbsp;Luis Villanueva MD, MSc","doi":"10.1002/cncr.70015","DOIUrl":"10.1002/cncr.70015","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Patients with recurrent glioblastoma (GBM) have a poor prognosis and limited treatment options. The authors report the efficacy and safety of lenvatinib plus pembrolizumab in participants with recurrent GBM enrolled in the phase 2, multicohort LEAP-005 study (NCT03797326).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Eligible participants had histologically confirmed GBM (World Health Organization grade IV) with disease progression since previous treatment, and one or more prior lines of therapy. Participants were enrolled regardless of tumor programmed cell death ligand 1 (PD-L1) status and received oral lenvatinib 20 mg per day plus intravenous pembrolizumab 200 mg every 3 weeks. The dual primary end points were objective response rate (ORR; per Response Assessment in Neuro-Oncology by blinded independent central review) and safety.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 101 participants were enrolled, with median (range) follow-up of 23.7 (16.4‒46.6) months. The median (range) duration of treatment with lenvatinib plus pembrolizumab was 3.4 (0.3‒32.2) months. The ORR (95% confidence interval [CI]) was 20% (13%‒29%), with 20 participants achieving a partial response, and the median (range) duration of response was 3.7 (1.4+ to 27.6) months. Median (95% CI) progression-free survival was 3.0 (2.7‒4.0) months and median (95% CI) overall survival was 8.6 (7.4‒10.8) months. Responses were observed regardless of PD-L1 status. Treatment-related adverse events occurred in 93 participants (92%; grade 3‒5, <i>n</i> = 41 [41%]). Two participants died due to treatment-related adverse events (intestinal perforation and pneumonitis).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The combination of lenvatinib plus pembrolizumab demonstrated antitumor activity in a small subpopulation of participants with recurrent GBM as second-line or later treatment. The safety profile was manageable.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 16","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144833201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peritransplant lysine methyltransferase 2a–rearranged measurable residual disease dynamics as a prognostic marker in adult acute myeloid leukemia","authors":"Lu-Lu Wang MD,&nbsp;Peng Zhao MD,&nbsp;Jing Liu PhD,&nbsp;Zhuo-Yu An MD,&nbsp;Hai-Xia Fu PhD,&nbsp;Chen-Cong Wang MD,&nbsp;Meng Lv PhD,&nbsp;Chen-Hua Yan PhD,&nbsp;Ting-Ting Han PhD,&nbsp;Yu-Hong Chen PhD,&nbsp;Jun Kong PhD,&nbsp;Yuan-Yuan Zhang PhD,&nbsp;Yao Chen PhD,&nbsp;Zhi-Dong Wang PhD,&nbsp;Wei Han PhD,&nbsp;Yun He PhD,&nbsp;Xiao-Dong Mo PhD,&nbsp;Feng-Rong Wang PhD,&nbsp;Jing-Zhi Wang PhD,&nbsp;Ying-Jun Chang PhD,&nbsp;Xiang-Yu Zhao PhD,&nbsp;Yu Wang PhD,&nbsp;Lan-Ping Xu PhD,&nbsp;Xiao-Jun Huang PhD,&nbsp;Xiao-Hui Zhang PhD","doi":"10.1002/cncr.70044","DOIUrl":"10.1002/cncr.70044","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This study examined the impact of measurable residual disease (MRD) dynamics in adults with lysine methyltransferase 2a rearrangement (<i>KMT2A</i>r) in acute myeloid leukemia (AML) during the peritransplant period (before and early after allogeneic hematopoietic stem cell transplantation [HSCT]).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study involved 144 adult patients with AML with <i>KMT2A</i>r who underwent HSCT between 2015 and 2024. Patients were enrolled if they survived without relapse for at least 3 months post-HSCT. MRD was measured via real-time quantitative polymerase chain reaction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The cohort was categorized into four groups on the basis of MRD status before and after HSCT, respectively: MRD negative/MRD negative (<i>n</i> = 81), MRD negative/MRD positive (<i>n</i> = 2), MRD positive/MRD negative (<i>n</i> = 43), and MRD positive/MRD positive (<i>n</i> = 18). Significant differences were found in 3-year overall survival (OS), leukemia-free survival (LFS), and cumulative incidence of relapse (CIR) (all <i>p &lt;</i> .001), with the MRD-negative/MRD-negative group having the best outcomes (88% OS, 85% LFS, and 10% CIR), whereas the MRD-negative/MRD-positive group (0% OS, 0% LFS, and 100% CIR) and MRD-positive/MRD-positive group (29% OS, 31% LFS, and 69% CIR) had the worst outcomes. The MRD-positive/MRD-negative group had an intermediate prognosis (63% OS, 58% LFS, and 32% CIR). Peri-HSCT MRD dynamics served as an independent factor, which distinguished patient groups with differential risk probabilities of mortality and relapse. <i>C</i>-statistic values were greater when peri-HSCT MRD dynamic testing was used than when isolated pre- or post-HSCT MRD was used to predict CIR (0.68 vs. 0.58 vs. 0.56), LFS (0.74 vs. 0.69 vs. 0.64), and OS (0.73 vs. 0.68 vs. 0.66).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Compared with single–time point MRD assessments, peritransplant MRD dynamics confer superior prognostic accuracy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 16","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144832599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mutational analysis of primary and advanced chordoma tissue using next-generation sequencing","authors":"Josh Chan BMSc,&nbsp;Joseph K. Kendal MD, MSc, FRCSC,&nbsp;Zhenfeng Duan MD, PhD,&nbsp;Al Ferreira RN,&nbsp;Alireza Samiei MD,&nbsp;Scott D. Nelson MD,&nbsp;Arun Singh MD,&nbsp;Elizabeth L. Lord MD,&nbsp;Brooke Crawford MD,&nbsp;Nicholas M. Bernthal MD,&nbsp;Francis J. Hornicek MD, PhD","doi":"10.1002/cncr.70033","DOIUrl":"10.1002/cncr.70033","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chordomas are rare ectodermal bone malignancies derived from transformed notochordal remnants. Histologic variants include conventional (80%–90%), chondroid (5%–15%), and dedifferentiated (2%–8%). Because chordomas are relatively resistant to chemotherapy and radiotherapy, novel targeted agents are needed to expand treatment approaches and improve outcomes. This study analyzes the genomic landscape of chordoma and identifies potential pathogenic and druggable targets.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Eighty-six tumor samples derived from chordoma patients treated at Massachusetts General Hospital, University of California, Los Angeles, and the University of Miami were included. Tumor specimens were sent for comprehensive molecular profiling using next-generation sequencing. The most frequently mutated genes were identified and categorized by subtype, and microsatellite instability and programmed death ligand-1 (PD-L1) staining were assessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Histologic subtypes included 70 conventional (81.4%), nine chondroid (10.5%), and seven dedifferentiated chordomas (8.1%). The most common mutations were cyclin-dependent kinase inhibitor 2A/B (<i>CDKN2A/B</i>) (28 of 86, 33%), low-density lipoprotein receptor-related protein 1B (10 of 86, 12%), polybromo-1 (9 of 86, 11%), and epidermal growth factor receptor (<i>EGFR</i>) (8 of 86, 9%). By subtype, <i>CDKN2A/B</i> mutation was most common in conventional chordoma (24 of 70, 34%), and chondroid chordoma (3 of 9, 33%). <i>CDKN2A/B</i> and <i>EGFR</i> mutations were most common in dedifferentiated chordoma (2/7, 29%). Microsatellite instability was not detected in seven of 69 (10.1%) samples. PD-L1 staining of tumor and immune cells was scarce, with scores &lt;1 in 38 of 41 (92.7%) and 22 of 25 (88%) patients, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study provides a robust, high-dimensional sequencing assessment from 86 chordoma tissue samples and a descriptive overview of the genomic landscape of this rare, difficult to treat malignancy. Future studies should include in vitro assessment of gain and loss of function of frequently altered pathways to validate these findings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 16","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70033","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144833200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The American Cancer Society National Lung Cancer Roundtable strategic plan: Addressing planning for lung cancer interventions at the state and local level through the creation of the National Lung Cancer Roundtable Planning Tool","authors":"Jessica M. G. Olson PhD, MPH,&nbsp;Jennifer R. Knight DrPH,&nbsp;Amy M. Copeland MPH,&nbsp;Kerstin A. Ohlander MS,&nbsp;Katie H. Bathje MA,&nbsp;Hannah C. Burson BA,&nbsp;Cindy A. Domingo BS,&nbsp;Kelly A. Durden MA,&nbsp;Elizabeth Dickson-Gavney MS,&nbsp;Korey E. Hofmann MPH,&nbsp;Timothy W. Mullett MD, MBA,&nbsp;Lauren S. Rosenthal MPH,&nbsp;Ella A. Kazerooni MD, MS,&nbsp;Douglas E. Wood MD,&nbsp;Robert A. Smith PhD","doi":"10.1002/cncr.35954","DOIUrl":"10.1002/cncr.35954","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lung cancer is the leading cause of cancer death in the United States, accounting for approximately 20% of cancer deaths nationwide. Despite national guidelines, uptake of lung cancer interventions varies across states because of differences in resources, insurance, policies, and infrastructure. Coalitions need a state-specific, web-based tool to develop targeted strategies. The American Cancer Society National Lung Cancer Roundtable recognized this gap and prioritized the development of a web-based State-Based Initiatives (SBI) Planning Tool to help coalitions personalize and streamline lung cancer efforts.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The SBI Task Group convened public health leaders, health care professionals, policymakers, and patient advocates to design a centralized, user-friendly tool. Inspired by the American Cancer Society National Colorectal Cancer Roundtable’s <i>Guide to the Development of State-Level Colorectal Cancer Coalitions</i>, the team iteratively refined the SBI Planning Tool through beta testing cycles, ensuring accessibility and relevance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The final SBI Planning Tool is a customizable, web-based platform in which coalitions develop action plans using state-specific data, interactive resources, and best practices. Key functionalities allow users to explore state-specific factors, such as existing lung cancer programs, coalition-building strategies, and policy environments, supporting a structured yet flexible approach to improving lung cancer outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The SBI Planning Tool represents a critical advancement in lung cancer control, offering an adaptable framework for states to strengthen their interventions based on real-world conditions. This tool equips state and local leaders with the resources needed to drive meaningful change, reduce disparities, and improve lung cancer prevention, screening, and treatment efforts nationwide.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 16","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35954","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144811145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Top advances of the year: Bladder cancer","authors":"Andrea B. Apolo MD,&nbsp;Saad Atiq MD,&nbsp;Andre R. Kydd MD, PhD,&nbsp;Raju Chelluri MD,&nbsp;Braden Millan MD,&nbsp;Sandeep Gurram MD,&nbsp;Elias Chandran MBBS,&nbsp;Nicholas Simon MD","doi":"10.1002/cncr.70020","DOIUrl":"10.1002/cncr.70020","url":null,"abstract":"<p>Looking back at 2024, the authors highlight the top five clinical advances in bladder cancer (urothelial carcinoma), from: (1) novel drug-delivery mechanisms in intravesical therapy for nonmuscle-invasive bladder cancer and muscle-invasive bladder cancer (MIBC); (2) immune checkpoint inhibition (ICI) as adjuvant and (3) perioperative therapy in MIBC; (4) circulating tumor DNA as a biomarker in MIBC; to (5) a new standard of care in first-line metastatic urothelial carcinoma. TAR-200 is a new intravesical drug-delivery system that enables controlled release of gemcitabine but may be used with other anticancer drugs to treat nonmuscle-invasive bladder cancer and MIBC. Two phase 3 studies of adjuvant ICI (nivolumab and pembrolizumab) have both reported a doubling of disease-free survival in patients with high-risk MIBC receiving therapy. Perioperative durvalumab, including neoadjuvant therapy plus gemcitabine and cisplatin before radical cystectomy followed by adjuvant durvalumab, demonstrated an improvement in event-free survival and overall survival for patients with MIBC. Circulating tumor DNA is a promising biomarker to select patients with MIBC for adjuvant ICI therapy. Finally, the combination of enfortumab vedotin, an antibody–drug conjugate, plus pembrolizumab doubled overall survival compared with standard gemcitabine plus platinum in patients with metastatic urothelial carcinoma and has been implemented in treatment guidelines in the United States, Europe, and Asia as the new standard of care in this setting, transforming the treatment landscape for bladder cancer.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 16","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144811447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus-built recommendations to improve prostate cancer outcomes: A summary of the American Cancer Society Prostate Cancer Collaborative","authors":"Jessie Sanders BA,&nbsp;Caleb Levell MA,&nbsp;Lucas J. Brand PhD,&nbsp;William L. Dahut MD,&nbsp;Yaw K. Nyame MD, MS, MBA,&nbsp;Lorelei Mucci ScD, MPH,&nbsp;William K. Oh MD,&nbsp;American Cancer Society Prostate Cancer Collaborative","doi":"10.1002/cncr.70010","DOIUrl":"10.1002/cncr.70010","url":null,"abstract":"<p>The incidence of prostate cancer in the United States has steadily risen since 2014, which has reversed decades of progress toward lowering the burden of prostate cancer. Mortality rates have plateaued, despite reliable screening methodology in the form of prostate-specific antigen testing, and despite a recent surge in the number of approved therapeutics for the management of primary and metastatic prostate cancer. If these trends are not addressed quickly and decisively via a multidisciplinary approach, loss of life and economic strain due to prostate cancer could precipitously increase in the coming years. To this end, the American Cancer Society (ACS) convened a collaborative of experts across the prostate cancer continuum to identify barriers to progress and generate opportunities for innovation. Through a series of consensus-building exercises and progressive refinement of themes into actionable priority areas, the collaborative identified three strategic priorities. These priorities form the backbone of an action plan to improve risk assessment and screening uptake, optimize therapeutic intervention for localized prostate cancer, and leverage the emerging arsenal of tools to more effectively manage advanced prostate cancer in the clinic. To advance this work, the ACS has launched the ACS National Prostate Cancer Roundtable to nucleate and coordinate partners from across the prostate cancer continuum to activate around these strategic priorities, and to build momentum toward improving prostate cancer outcomes for all.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 16","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144811443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation","authors":"Sankalp Arora MD,&nbsp;Wei-Ying Jen MD,&nbsp;Musa Yilmaz MD,&nbsp;Indraneel Deshmukh MD,&nbsp;Jayastu Senapati MD,&nbsp;Sanam Loghavi MD,&nbsp;Ghayas C. Issa MD,&nbsp;Nicholas J. Short MD,&nbsp;Tapan M. Kadia MD,&nbsp;Courtney D. DiNardo MD,&nbsp;Gautam Borthakur MD,&nbsp;Joseph Jabbour,&nbsp;Naveen Pemmaraju MD,&nbsp;Michael Andreeff MD, PhD,&nbsp;Koichi Takahashi MD, PhD,&nbsp;Kapil Bhalla MD,&nbsp;Uday Popat MD,&nbsp;Elizabeth J. Shpall MD,&nbsp;Betul Oran MD,&nbsp;Hussein A. Abbas MD, PhD,&nbsp;Guillermo Garcia-Manero MD,&nbsp;Farhad Ravandi MD,&nbsp;Hagop Kantarjian MD,&nbsp;Naval Daver MD","doi":"10.1002/cncr.70032","DOIUrl":"10.1002/cncr.70032","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The prognostic impact of Fms-like tyrosine kinase 3 (&lt;i&gt;FLT3&lt;/i&gt;)-tyrosine kinase domain (TKD) mutation in patients with acute myeloid leukemia (AML) is not well defined. The authors described outcomes of one of the largest cohorts of patients with &lt;i&gt;FLT3&lt;/i&gt;-TKD mutated (&lt;i&gt;FLT3&lt;/i&gt;-TKD&lt;sup&gt;mut&lt;/sup&gt;) AML to date.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This retrospective study included patients with newly diagnosed AML who received frontline treatment at The University of Texas MD Anderson Cancer Center from January 2012 to March 2024 divided into two cohorts: &lt;i&gt;FLT3&lt;/i&gt;-TKD&lt;sup&gt;mut&lt;/sup&gt; AML and nucleophosmin-mutated (&lt;i&gt;NPM1&lt;/i&gt;&lt;sup&gt;mut&lt;/sup&gt;)/&lt;i&gt;FLT3&lt;/i&gt;-TKD wild-type (&lt;i&gt;FLT3&lt;/i&gt;-TKD&lt;sup&gt;wt&lt;/sup&gt;) AML. Patients with &lt;i&gt;FLT3&lt;/i&gt; internal tandem duplication mutations were excluded.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In total, 2922 patients were screened, and 250 met inclusion criteria, including 124 patients with &lt;i&gt;FLT3&lt;/i&gt;-TKD&lt;sup&gt;mut&lt;/sup&gt; AML and 126 patients with &lt;i&gt;NPM1&lt;/i&gt;&lt;sup&gt;mut&lt;/sup&gt;/&lt;i&gt;FLT3&lt;/i&gt;-TKD&lt;sup&gt;wt&lt;/sup&gt; AML. In the &lt;i&gt;FLT3&lt;/i&gt;-TKD&lt;sup&gt;mut&lt;/sup&gt; cohort (&lt;i&gt;n&lt;/i&gt; = 124), intensive chemotherapy was received by 54 patients (44%), with a composite complete remission in 81% and a 3-year overall survival (OS) rate of 56%. An &lt;i&gt;NPM1&lt;/i&gt; mutation was noted in 24 patients (44%) who had improved OS (3-year OS, 74% vs. 40%; &lt;i&gt;p&lt;/i&gt; = .03). Allogeneic stem cell transplantation improved OS in patients who had &lt;i&gt;NPM1&lt;/i&gt;&lt;sup&gt;wt&lt;/sup&gt; AML (3-year OS, 89% vs. 30%; &lt;i&gt;p&lt;/i&gt; = .02) but not in those who had an &lt;i&gt;NPM1&lt;/i&gt; mutation. Lower intensity therapy was received by 70 patients (56%), with a composite complete remission in 63% and a 3-year OS rate of 23%. An &lt;i&gt;NPM1&lt;/i&gt; mutation was noted in 31 patients (44%) who had improved OS (3-year OS, 32% vs. 16%; &lt;i&gt;p&lt;/i&gt; = .04). Allogeneic stem cell transplantation led to a trend toward improved OS in patients who had &lt;i&gt;NPM1&lt;/i&gt;&lt;sup&gt;wt&lt;/sup&gt; AML (3-year OS, 75% vs. 27%; &lt;i&gt;p&lt;/i&gt; = .1) but not in those who had &lt;i&gt;NPM1&lt;/i&gt;&lt;sup&gt;mut&lt;/sup&gt; AML. In the &lt;i&gt;NPM1&lt;/i&gt;&lt;sup&gt;mut&lt;/sup&gt;/&lt;i&gt;FLT3&lt;/i&gt;-TKD&lt;sup&gt;wt&lt;/sup&gt; cohort (&lt;i&gt;n&lt;/i&gt; = 126), intensive chemotherapy was received by 46 patients (37%), and lower intensity therapy was received by 80 patients (63%). Compared with the &lt;i&gt;NPM1&lt;/i&gt;&lt;sup&gt;mut&lt;/sup&gt;/&lt;i&gt;FLT3&lt;/i&gt;-TKD&lt;sup&gt;mut&lt;/sup&gt; cohort, no difference in OS was noted between patients who received intensive chemotherapy and those who received lower intensity therapy.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;&lt;i&gt;FLT3-&lt;/i&gt;TKD&lt;sup&gt;mut&lt;/sup&gt; AML co","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 16","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144811446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and cost of implementing a patient navigation program to increase colorectal cancer screening in a large federally qualified health center","authors":"Florence K. L. Tangka PhD,&nbsp;Esmeralda Ruiz MPH,&nbsp;Raylene Ibarra BA,&nbsp;Sharon M. Hudson PhD,&nbsp;Valerie Richmond-Reese BA,&nbsp;Sonja Hoover MPP,&nbsp;Mark Krudy BA,&nbsp;Sujha Subramanian PhD","doi":"10.1002/cncr.70031","DOIUrl":"10.1002/cncr.70031","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The purpose of this study was to evaluate the effectiveness and cost of a patient navigation (PN) program in a large federally qualified health center (FQHC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The PN program implemented at AltaMed was evaluated; it is an FQHC that participated in the Centers for Disease Control and Prevention’s Colorectal Cancer Control Program. A tailored data collection tool was developed to collect time and resources spent on program activities, salaries of staff, nonlabor resources, and process and outcome measures for 2021–2023. Sociodemographic characteristics and screening uptake for 2020–2023 was collected. Screening uptake and percentage of stool-based tests returned by year and intervention type and compared process measures was calculated, as was the cost of strategies used to increase uptake of stool-based colorectal cancer screening tests.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The percentage of fecal immunochemical tests (FIT) returned among those receiving the PN program ranged from 36.6% in 2021 to 51.0% in 2023. The total annual cost for PN, mailings of FITs, and cost of the FIT kits ranged from $328,000 to $388,000 across the 3 years. The FQHC cost per person completing FITs decreased from $32 in 2021 to $25 in 2023. The total cost (FQHC and payer reimbursement) was calculated at $54 in 2021, $44 in 2022, and $47 in 2023 for each person completing FIT. The total cost was $512 in 2022 and $513 in 2023 per person completing Cologuard.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The PN program, which used reminder texts and calls, alongside mass mailings of stool kits, increased kit returns over the implementation period.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 16","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144811444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}